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The colon is subject to oxidative and free radical damage by both
products of endogenous metabolism and bacterial fermentation
within the gut lumen. These injurious stimuli may cause cell
damage or cell death or even lead to mutations, resulting in tumour
initiation and progression. Colon cancer is a common disease, with
the highest incidence in developed countries. The aetiology is
unknown, but in addition to diet and cigarette smoking
(Giovannucci and Willett, 1994) there is a complex polygenic
background that determines individual susceptibility to disease.
There is currently much interest in the roles of oncogenes, tumour-
suppressor genes and mismatch repair enzymes in colon cancer
(Tomlinson et al, 1997). In addition, interindividual variation in
the ability to dispose of reactive xenobiotics catalysed by
glutathione S-transferases GST-M1 and GST-T1 has been investi-
gated (Lang et al, 1986; Strange et al, 1991; Zhong et al, 1993;
Chenevix-Trench et al, 1995). However, results from a number of
studies show only weak and inconsistent associations with disease
susceptibility. N-acetyltransferase 2 (NAT-2) polymorphism may
be implicated in susceptibility to colon cancer (Lang et al, 1986;
Wohlleb et al, 1990; Illett et al, 1994; Probst-Hensch et al, 1995),
but there is evidence that its relationship may be by linkage with
other genes rather than causally (Hubbard et al, 1997).
We have used a polymerase chain reaction (PCR) strategy to
investigate whether polymorphisms in the microsomal epoxide
hydrolase gene (mEPHX) (Hassett et al, 1994) have any relation-
ship to colon cancer. The enzyme is expressed in many tissues,
including colon and liver. Polymorphisms of mEPHX may have
functional significance. There is variation in exon 3, where a T to
C alteration changes tyrosine residue 113 to histidine and is
associated with lower enzyme activity when expressed in vitro. By
contrast, A to G transition in exon 4 changes histidine residue 139
to arginine and produces increased enzyme activity. The effect of
combining the alleles has not been established. The activity of
mEPHX varies more than 50-fold in Caucasians (Omiecinski et al,
1993). This variation of activity is, thus, due to a combination of
genetic polymorphism, transcriptional and post-transcriptional
control of gene expression.
MATERIALS AND METHODS
Controls and cancer cases
Control blood samples (n = 203) were obtained anonymously from
the Scottish National Blood Transfusion Service. These were
Caucasian individuals aged between 18 and 65 years with equal sex
distribution. This group has been previously described (Cantlay et
al, 1994) and was drawn from the same geographical area as the
cancer study group. The presence of colorectal neoplasia was not
specifically excluded, but all patients were healthy. Peripheral
blood from patients with colorectal cancer was collected from a
consecutive series of operable colorectal cancer cases after surgery
in four local hospitals between 1988 and 1993 (n = 101).
Cancer patient data
Cancer diagnosis was confirmed histopathologically and cases
were classified according to Dukes’ stages (A, B, C), and
according to position of cancer in the colon as either right
(caecum, transverse or ascending) or left (sigmoid, descending or
rectum) sides. All samples were Caucasian in origin. DNA was
extracted as previously described (Cantlay et al, 1995). In addi-
tion, the frequency of immunodetectable stabilization of p53 was
recorded using antibody DO7 (Dako) on formalin-fixed, paraffin-
embedded tissue (n = 92). Loss of heterozygosity at the p53 locus
on chromosome 17 (n = 93) was determined as previously reported
(Cripps, 1994). The presence of codon 12 mutations in Ki-ras
oncogene was determined using allele-specific PCR (n = 81) as
described previously (Kotsinas et al, 1993).
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mEPHX PCR analysis
Two separate PCR assays were used to detect the two mutations in
mEPHX. The assay for the exon 3 T to C variant, changing tyrosine
113 to histidine, uses the primer pair E1 5¢-GATCGATAAGTTC-
CGTTTCACC [starting at bp 321 in mEPHX cDNA] and E2 5¢-
ATCCTTAGTCTTGAAGTGAGGaT (starting at bp 461). The
downstream primer abuts directly onto the mutation site and an
engineered base change (shown in lower case: an A for a G)
produces an EcoRV restriction enzyme site (GATATC) in the wild
type only. The exon 4 A to G transition produces an RsaI restriction
fragment length polymorphism (ATAC to GTAC). The primer pair
E3 5¢-ACATCCACTTCATCCACGT (bp 494) and E4 5¢-ATGC-
CTCTGAGAAGCCAT (bp 685) is used to assay this poly-
morphism. Figure 1 shows a typical result of the genotyping assays.
Polymorphisms were detected using restriction enzymes EcoRV
(exon 3) and RsaI (exon 4). The polymerase chain reaction was
performed on a Hybaid Omnigene thermal cycler using 200 ng of
genomic DNA, 200 ng of primers E1/E2 or E3/E4, 200 mM dNTPs
(Pharmacia, UK), ´1 polymerase buffer (Promega, UK), 1.5 mM
magnesium chloride, 4% DMSO and 2 u of Taq Polymerase
(Promega, UK) in a total volume of 50 ml. Twenty microlitres of
each PCR reaction was digested with 5 u of the appropriate restric-
tion enzyme (Gibco BRL, UK). Digested PCR products were sepa-
rated by size on 1.8% Metaphor (Hoeffer Scientific) agarose gel.
Bands were visualized by ethidium bromide staining and ultraviolet
illumination. Main cycling parameters were: 38 cycles of 94°C for
30 s, 55°C for 25 s and 72°C for 20 s.
Statistical analysis
Associations between disease groups and specific genotypes and
phenotypes were analysed for significance by the two-tailed chi-
squared test and P-values were Bonferroni corrected. Odds ratios
and 95% confidence intervals were calculated to assess relative
risk of disease conferred by a particular allele or genotype.
RESULTS
mEPHX gene analysis
Analysis of the control group showed that the exon 3 histidine 113
(‘slow’) form was threefold more common than the exon 4 argi-
nine 139 (‘fast’) form in the Caucasian population; 13 (6%) out of
Table 1 Distribution of microsomal epoxide hydrolase genotypes in control and disease populations
Exon 3 polymorphism Exon 4 polymorphism
Tyr Tyr/His His c2 (P-value) OR (95% CI) MAF His His/Arg Arg c2 (P-value) MAF
(%) (%) (%) (%) (%) (%)
Controls (n = 203) 91 99 13 – – 0.31 147 53 3 – 0.15
(45) (49) (6) (72) (26) (2)
Colorectal cancer (n = 101) 42 38 21 14.5 3.84 (1.83–8.04) 0.40 76 21 4 2.66 0.15
(50) (40) (10) 0.007 (75) (21) (4) >0.10
Right-sided (n = 33) 11 16 6 5.7 3.25 (1.14–9.27) 0.43 21 9 3 6.79 0.23
(33) (49) (18) >0.10 (64) (27) (9) >0.10
Left-sided (n = 68) 31 22 15 15.2 4.10 (1.87–9.15) 0.38 55 12 1 2.0 0.10
(46) (32) (22) 0.002 (81) (18) (1) >0.10
For exon 3 genotype, the designation ‘Tyr’ represents an individual carrying homozygous Tyr113 mEPHX sequence, ‘His’ represents a homozygous His-113
and ‘Tyr/His’ a heterozygote. For exon 4 genotype, the designation ‘His’ represents an individual carrying homozygous His-139 mEPHX sequence, ‘Arg’
represents a homozygous Arg-139 and ‘His/Arg’ a heterozygote. P-values for c2 for right- and left-sided compared with controls are given as Bonferroni
corrected. Odds ratios (OR) and 95% confidence intervals (CI), relative risk of the presence of two His-113 exon 3 alleles in disease population vs controls.
MAF = ‘mutant’ allele frequency.
Table 2 Distribution of mEPHX exon 3 genotypes and p53
immunodetection, p53 loss of heterozygosity and Ki-ras codon 12 mutation
Exon 3 polymorphism
Tyr (%) Tyr/His (%) His (%) P-value
p53 immunodetection (n = 92)
Positive 17 (18) 13 (14) 9 (10) >0.10
Negative 21 (23) 22 (24) 10 (11)
p53 loss of heterozygosity (n = 93)
Loss 8 (9) 9 (10) 3 (3) >0.10
Retained 11 (12) 8 (9) 4 (4)
Non-informative 21 (22) 17 (18) 12 (13)
Ki-Ras mutation at codon 12 (n = 81)
Wild type 7 (9) 6 (7) 5 (6) >0.10
Mutated 28 (34) 24 (30) 11 (14)
Nomenclature of mEPHX exon 3 alleles as described in Table 1. P-value
calculated from c2 comparing exon 3 allele frequency within each group, for
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203 individuals were homozygous for histidine 113 (exon 3) and
49% heterozygous. In comparison, arginine 139 (exon 4) was only
detected in 28% of individuals, with only three homozygous
subjects in total (Table 1). These results are similar to previous
studies (Smith and Harrison, 1997).
mEPHX polymorphisms in disease groups
The distribution of mEPHX genotypes are shown in Table 1, and
the comparison of exon 3 alleles with p53 and Ki-ras mutations
shown in Table 2. In the group of colon cancer patients (Table 1),
there was a significant increase in the proportion of individuals
homozygous for the histidine 113 (exon 3) [P = 0.007; odds ratio
(OR) = 3.84]. Twenty-one out of 101 patients (21%) were
homozygous for the histidine 113 (exon 3, putative ‘slow’ activity)
versus only 6% of controls. There was no significant difference in
the distribution of arginine 139 (exon 4, putative ‘fast’ activity)
between control and cancer groups. Cancers were divided into
right- and left-sided groups and the association with histidine 113
polymorphism was recalculated. For right-sided tumours, there
was a trend for the putative ‘slow’ allele to be more common in the
cancer group, but this was not statistically significant when the
Bonferroni correction was applied. By contrast, left-sided colon
cancers showed a highly significant increase in histidine 113
‘slow’ allele compared with controls (P = 0.002; OR = 4.1). No
association with sex, age or Dukes’ stage was found for either
allele (data not shown). No association between arginine 139 poly-
morphism and right- or left-sided tumours was identified. When
compared with the frequency of immunodetectable stabilization of
p53, loss of heterozygosity at the p53 locus, or codon 12 mutation
of Ki-Ras, no association was noted with polymorphisms of
mEPHX at either exon 3 or exon 4 (Table 2). Comparisons of the
observed distributions of mEPHX genotypes and those predicted
by allele frequencies by chi-squared analysis showed that the
populations studied were in Hardy–Weinberg equilibrium, indi-
cating that the control and study groups were sufficiently random
and representative (data not shown).
DISCUSSION
The demonstration that genetically defined polymorphisms in
mEPHX, predicted to affect enzyme activity at least in part, are
associated with an increased incidence of colorectal cancer
suggests that reactive epoxide intermediate metabolites may play a
role in the development of colon cancer. Individuals with histidine
113 instead of tyrosine 113 (exon 3) had more than a threefold rela-
tive risk of having colorectal cancer. This is particularly true for
cancers arising in the left side of the colorectum, i.e. descending
and sigmoid colon and rectum, in which the relative risk increased
to more than 4. The absence of a correlation with p53 or Ki-ras
mutations is unsurprising. mEPHX is a protective enzyme involved
in general oxidative defence, rather than in specific protection of
individual genes. Previously studies describing weak association
between glutathione-dependent enzymes and colorectal cancer
have found that the risk is more consistently with tumours origi-
nating in the left side (Zhong et al, 1993). This site may be more at
risk from oxidative stress, or may be more likely to have high expo-
sure to oxidants because of the higher transit time for faecal mate-
rial at this site. Epoxides may be present in diet, or generated from
a number of sources, including benzpyrene (which is present in
cigarette smoke), dietary polycyclic aromatic hydrocarbons and
nitrosamines (Craft et al, 1988; Yang et al, 1988). Some further
evidence suggests that mEPHX may be involved in steroidogenesis
reactions which may explain preliminary observations that ‘slow’
genotype may be protective for ovarian cancer (Lancaster et al,
1996) and is not involved in lung (Smith et al, 1997) or bladder
(Brockmoller et al, 1996) cancer risk.
The present study has examined genotype and not phenotype.
There is clear evidence that the presence of a ‘slow’ exon 3 allele
does confer lower enzyme activity, but genotype alone is insuffi-
cient to explain the variation of microsomal epoxide hydrolase
enzyme activity seen in population studies (Hassett et al, 1997). In
particular, the effect of carrying both exon 3 and exon 4 poly-
morphisms is undetermined and, thus, assumptions concerning
enzyme activity from our study should be necessarily guarded. It is
still possible that the described mutations are of themselves not
causally related to colon cancer, but rather are in linkage with
other, as yet unidentified, factors. However, the clear association
does indicate that this enzyme is an important candidate to relate
diet with susceptibility of the colorectal mucosa to injury.
Evidence that dietary supplements, particularly fish oils which are
thought to be chemopreventative for colon cancer, can induce
microsomal epoxide hydrolase (Yang et al, 1993) and, thus,
increase enzyme activity further strengthens this association and
indicates the need for further investigation.
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